Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
Ottawa Hospital Research Institute
Ottawa Hospital Research Institute
Washington University School of Medicine
Washington University School of Medicine
Swiss Cancer Institute
Alliance for Clinical Trials in Oncology
Washington University School of Medicine
Stony Brook University
Kyoto Prefectural University of Medicine
Amgen
Amgen
Institut Català d'Oncologia
M.D. Anderson Cancer Center
Amgen
Ottawa Hospital Research Institute
NYU Langone Health
Borstkanker Onderzoek Groep
M.D. Anderson Cancer Center
Amgen
Parc de Salut Mar
Jules Bordet Institute
Northwestern University
Amgen
Amgen
Amgen
Amgen